Aralast, Aralast NP (Takeda) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities include increased early diagnosis of AATD, growing adoption of AAT augmentation therapy, expanded awareness of genetic respiratory disorders, and advancements in plasma-derived therapies. Rising healthcare expenditure and R&D activities also drive growth, particularly in Asia-Pacific.

Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Aralast, Aralast Np Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.
The Aralast market research report offers comprehensive industry insights, highlighting market size, regional shares, and competitive analysis. It delves into the sales of alpha-1 proteinase inhibitor products and related services.

Aralast and Aralast NP are pivotal therapies used for conditions like AATD and COPD, distributed through diverse channels including hospitals and specialty clinics. The market reflects factory gate values and considers revenues from direct sales, contributing to the expansive growth trajectory forecasted across various regions.

The Aralast and Aralast NP market is experiencing significant growth due to a variety of factors. In the historic period, the rise in growth can be attributed to the clinical validation of AAT augmentation therapy, an increasing COPD patient population, improved genetic screening for AATD, specialist pulmonology adoption, and the availability of plasma-derived therapies. Moving forward, the growth forecast is spurred by earlier AATD diagnosis rates, expansion of awareness for rare respiratory diseases, enhanced access to specialty clinics, improved therapy adherence, and advancements in plasma fractionation processes.

Several trends are contributing to the market's expansion. These include the increased diagnosis of Alpha-1 Antitrypsin Deficiency, growing adoption of augmentation therapy for COPD, and expansion of long-term plasma-derived protein therapies. Further, there is improved awareness of genetic respiratory disorders and an increase in preventive pulmonology care usage.

The prevalence of genetic disorders is expected to further drive market growth. Aralast and Aralast NP play a crucial role in managing genetic disorders by providing essential AAT replacement therapy for those with AAT deficiency. This therapy is pivotal for slowing disease progression and enhancing respiratory health. The growing availability of genetic testing supports the expansion of the Aralast market, highlighted by an increase in hereditary hemophilia A patients, as reported by the National Blood Authority in Australia.

The rise in healthcare expenditure plays a crucial role in supporting the Aralast market. Increased spending enhances access to essential Alpha-1 Antitrypsin therapies, providing avenues for earlier diagnosis and more efficient management of the deficiency. For example, the UK's healthcare expenditure saw significant growth, as noted by the Office for National Statistics.

Research and development activities are central to propelling the market further. R&D fosters safer, more effective therapies that improve treatment precision and outcomes. Innovations in A1PI formulations and manufacturing processes will ensure consistent performance, as indicated by a rise in government budget allocations for R&D in the EU, according to Eurostat.

Major companies leading the market, such as Takeda Pharmaceutical Company Limited, contribute significantly, with North America holding the largest market share, followed by fast growth expected in the Asia-Pacific region. Tariffs have had a moderate impact by increasing costs related to plasma collection and fractionation equipment, but they also prompt regional investments in plasma processing and manufacturing, supporting long-term supply resilience.

Major Trends

• Rising Diagnosis of Alpha 1 Antitrypsin Deficiency
• Growing Adoption of Augmentation Therapy for COPD
• Expansion of Long Term Plasma Derived Protein Therapies
• Improved Awareness of Genetic Respiratory Disorders
• Increasing Use in Preventive Pulmonology Care

Report Scope

• Indication: Alpha-1 Antitrypsin Deficiency (AATD); Chronic Obstructive Pulmonary Disease (COPD); Liver Disease
• Distribution Channel: Direct Sales; Wholesale Distributors
• End User: Hospitals; Specialty Clinics; Pharmacies
• Companies Mentioned: Takeda Pharmaceutical Company Limited
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Market size and growth ratios, GDP proportions, expenditure per capita.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN11052026004107003653ID1111097345